AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
4,976.00
+20.50 (+0.41%)
At close: 4:36PM BST
Stock chart is not supported by your current browser
Previous Close4,955.50
Open4,971.50
Bid4,895.00 x 6100
Ask5,020.00 x 13000
Day's Range4,960.00 - 4,986.50
52 Week Range4,260.00 - 5,520.00
Volume1,433,699
Avg. Volume2,495,917
Market Cap63.026B
Beta0.98
PE Ratio (TTM)21.00
EPS (TTM)237.00
Earnings DateMay 18, 2018
Forward Dividend & Yield2.02 (4.12%)
Ex-Dividend Date2018-02-15
1y Target Est78.16
  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks2 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
    Zacks3 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

    AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

  • Reuters3 days ago

    AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

    U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

  • Industry fears disruption as EU excludes UK from drug approvals
    Reuters4 days ago

    Industry fears disruption as EU excludes UK from drug approvals

    A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients. The move confounds hopes for continued joint cooperation via the European Medicines Agency (EMA), at least during a transition or implementation period until the end of 2020 when the UK will remain closely tied to the European Union. Prime Minister Theresa May said in a speech on March 2 that London wanted to explore ways to keep Britain a part of EU agencies, such as the EMA.

  • An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued
    Simply Wall St.5 days ago

    An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued

    How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
    Zacks11 days ago

    Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

    Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

  • Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
    Zacks12 days ago

    Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

    Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

  • Top Analyst Reports for Microsoft, Merck & Union Pacific
    Zacks13 days ago

    Top Analyst Reports for Microsoft, Merck & Union Pacific

    Top Analyst Reports for Microsoft, Merck & Union Pacific

  • MarketWatch13 days ago

    Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca

    Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis ...

  • Reuters13 days ago

    Ionis to get up to $300 mln from licensing deal with AstraZeneca

    Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties. ...

  • Reuters13 days ago

    South Africa may ask pharma firms for fee to clear drug review backlog

    Drugmakers in Africa's largest pharmaceutical market may be asked to pay a "backlog fee" to help clear a pipeline of medicines waiting years for approval, according to a proposal being considered by South Africa's new industry regulator. Delays for hundreds of medicines have kept the latest treatments off South African shelves and hampered the fight against cancer, heart and other diseases in a country which also has more people receiving anti-retroviral drugs (ARVs) than anywhere else in the world. "It's the first time South Africa offers this and we would support a backlog fee, provided it is performance driven," said Stavros Nicolaou, senior executive for strategic trade at Aspen Pharmacare.

  • Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
    Zacks16 days ago

    Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

    Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

  • 3 Emerging Technologies Set to Transform the Pharma World
    Zacks17 days ago

    3 Emerging Technologies Set to Transform the Pharma World

    Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.

  • ACCESSWIRE17 days ago

    Wired News – Merck and AstraZeneca Announced that EMA Will Review MAA for LYNPARZA(R) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

    LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Merck & Co., Inc. (NYSE: MRK ) ("Merck"). If you want access to this report all you ...

  • Pfizer Has Big Plans in Treating Lung Cancer
    Motley Fool17 days ago

    Pfizer Has Big Plans in Treating Lung Cancer

    The filing for approval of two new lung cancer drugs positions the company to increase its market share in the indication.

  • AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
    Zacks18 days ago

    AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use

    AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.

  • Reuters18 days ago

    PRESS DIGEST- Financial Times - April 4

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines WPP probes misconduct allegation against Sorrell https://on.ft.com/2GuttQE ...

  • Reuters19 days ago

    UK Stocks-Factors to watch on April 3

    (Adds company news items and futures) April 3 (Reuters) - Britain's FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers, with futures down 1.15 percent ...

  • Reuters20 days ago

    Deals of the day-Mergers and acquisitions

    (Adds Elliott, COFCO Property, ReNew Power, General Electric; Updates Transcontinental) April 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ...

  • Reuters20 days ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • Reuters20 days ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • When Will They Learn? 4 Huge Biotech Blowups
    Motley Fool25 days ago

    When Will They Learn? 4 Huge Biotech Blowups

    AbbVie isn't the first big drugmaker to pay billions for a dud. Here's what you can learn from their mistakes.

  • Tesaro Wants a Stronger Grip in Ovarian Cancer
    Motley Fool25 days ago

    Tesaro Wants a Stronger Grip in Ovarian Cancer

    Management revealed data this week that could help the company against its competitors.

  • Reuterslast month

    GlaxoSmithKline prescribes commercial reboot for pharma division

    In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritised plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.